Drugs / Granisetron
Granisetron
also known as
granisetron hydrochloride · Sancuso · APF530 · AZ-010 · GTDS · Kytril · Staccato Granisetron · Bema granisetron · +23 more
Other / unclassified targets HTR3A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed chemotherapy-induced toxicity 1 milestone | |||||
| Filed | US (FDA) | SUSTOL | chemotherapy-induced toxicity | 2015-07-20 | “resubmitted its New Drug Application (NDA) for SUSTOL® (granisetron) Injection, extended release, for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)” herontx.com ↗ “In July 2015, Heron resubmitted its New Drug Application (NDA) for SUSTOL®” herontx.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Approved | EU (EMA) | Sancuso | — | 2012-04-20 | europa.eu ↗ |
| Label expansions (5) | US (FDA) | KYTRIL | — | 1997-01-21 – 2011-04-29 | fda.gov ↗ |
| Approved | US (FDA) | KYTRIL | — | 1993-12-29 | fda.gov ↗ |
Trials 52
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials · 2 met primary | ||||||
| Phase 1 | NCT01649258 | Sep 2012 → May 2017 | breast cancer | University of Southern California | Terminated | No outcome recorded |
| Phase 1 | NCT01596400 | May 2012 → Aug 2015 | chemotherapy-induced toxicity | Kyowa Kirin Pharmaceutical Development Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00890565 | May → Aug 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00873197 | Apr → May 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00868764 | Apr → Sep 2009 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00511823 | Jul → Sep 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00834717 | Sep 2005 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00834522 | Jul 2005 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT01596413 | — | chemotherapy-induced toxicity | Kyowa Kirin Pharmaceutical Development Ltd | Withdrawn | No outcome recorded |
| Phase 1 | NCT01596426 | — | chemotherapy-induced toxicity | Kyowa Kirin Pharmaceutical Development Ltd | Withdrawn | No outcome recorded |
| Phase 212 trials · 1 missed | ||||||
| Phase 2 | NCT05325190 | Oct 2021 → Dec 2022 | chemotherapy-induced toxicity | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04645953 | Feb 2021 → Jul 2022 | cyclic vomiting syndrome | Alexza Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT04472143 | Jul 2020 → Sep 2022 | chemotherapy-induced toxicity | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT03924518 | Apr 2019 → Nov 2020 | infectious disease with sepsis | Zhujiang Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04501211 | Jan 2019 → Dec 2020 | gastroparesis | Indiana University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02457195 | Feb 2016 → Feb 2018 | — | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01909856 | Oct 2011 → Apr 2014 | cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01183481 | Jan 2011 → Mar 2013 | — | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00787566 | Oct 2008 → Apr 2009 | chemotherapy-induced toxicity | Shin Nippon Biomedical Laboratories, Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00503386 | Apr → Oct 2006 | — | Hangzhou Jiuyuan Gene Engineering Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00450853 | Apr → Nov 2005 | — | Clinica Universidad de Navarra, Universidad de Navarra | Completed | No outcome recorded |
| Phase 2 | NCT01952886 | ? → Sep 2014 | malignant glioma | Duke University | Withdrawn | No outcome recorded Stop: Business |
| Phase 316 trials · 4 met primary · 1 missed | ||||||
| Phase 3 | NCT06281418 | Feb → Dec 2024 | — | Future University in Egypt | Completed | No outcome recorded |
| Phase 3 | NCT04912271 | Jun 2021 → Jun 2022 | chemotherapy-induced toxicity | Fudan University | Unknown | Met primary |
| Phase 3 | NCT05087615 | Mar → Aug 2021 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT03817970 | Nov 2019 → Sep 2027 expected | cisplatin toxicity | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03483350 | Mar → Aug 2018 | — | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT02106494 | Mar 2014 → May 2015 | chemotherapy-induced toxicity | Heron Therapeutics | Completed | Met primary |
| Phase 3 | NCT01937156 | Aug 2013 → Jan 2014 | chemotherapy-induced toxicity | Solasia Pharma K.K. | Completed | No outcome recorded |
| Phase 3 | NCT01989221 | Nov 2012 → Dec 2018 | gastroparesis | Temple University | Completed | No outcome recorded |
| Phase 3 | NCT01536392 | Mar 2012 → Oct 2019 | cervical cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00475085 | Dec 2006 → Dec 2012 | — | Joseph Roscoe | Completed | Mixed |
| Phase 3 | NCT00343460 | Jun 2006 → Sep 2008 | cancer of unknown primary site | Heron Therapeutics | Completed | Met primary |
| Phase 3 | NCT00273468 | Jan → Oct 2006 | chemotherapy-induced toxicity | Kyowa Kirin, Inc. | Completed | Met primary |
| Phase 3 | NCT00020657 | Jul 2001 → Oct 2004 | cancer of unknown primary site | Gary Morrow | Completed | Missed primary |
| Phase 3 | NCT00003213 | May 1996 → Apr 1999 | cancer of unknown primary site | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00005024 | — | cancer of unknown primary site | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 3 | NCT00004219 | — | testicular germ cell tumor | Simbec Research | Unknown | No outcome recorded |
| Phase 410 trials · 2 met primary | ||||||
| Phase 4 | NCT07360431 | Mar 2026 → Oct 2027 expected | — | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07401745 | Jan → Jul 2026 overdue | temporomandibular joint disorder | Mansoura University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05434663 | Jul 2022 → Oct 2025 | chemotherapy-induced toxicity | Heron Therapeutics | Unknown | No outcome recorded |
| Phase 4 | NCT06454825 | Apr 2020 → Apr 2021 | disorder of facial skeleton | Bezmialem Vakif University | Completed | Met primary |
| Phase 4 | NCT06043336 | May 2018 → May 2019 | — | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Phase 4 | NCT03503292 | May 2018 → Dec 2019 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01662687 | Feb → Oct 2012 | chemotherapy-induced toxicity | LG Life Sciences | Unknown | Met primary |
| Phase 4 | NCT01659775 | Aug 2011 → Nov 2012 | chemotherapy-induced toxicity | LG Life Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00231478 | Apr → Dec 2007 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT02230371 | Mar 2007 → Oct 2014 | myofascial pain syndrome, temporomandibular joint disorder | Karolinska Institutet | Completed | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06175806 | Sep → Nov 2023 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT01843868 | Jan 2012 → Jun 2015 | non-Hodgkin lymphoma | Australasian Leukaemia and Lymphoma Group | Withdrawn | No outcome recorded Stop: Enrollment |
| — | NCT01275664 | Jun 2011 → May 2014 | fallopian tube cancer, ovarian Brenner tumor, ovarian clear cell cystadenocarcinoma, ovarian endometrioid adenocarcinoma +5 | Gynecologic Oncology Group | Terminated | No outcome recorded |
| — | NCT00502437 | — | — | Hadassah Medical Organization | Unknown | No outcome recorded |
| Comparator or background therapy52 trials | ||||||
| Phase 0 | NCT04290026 Comparator | Apr 2021 → Jan 2022 | aspiration pneumonia | Assiut University | Unknown | No outcome recorded |
| Phase 1 | NCT04200092 Comparator | Nov 2019 → Jan 2020 | — | Nova Pneuma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03333824 Background | Dec 2017 → Jan 2019 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02563951 Comparator | Sep → Dec 2015 | cancer | Maxinase Life Sciences Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01073696 Comparator | Mar → Apr 2010 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT06031090 Comparator | Mar → Oct 2023 | benign shuddering attacks | Zagazig University | Unknown | No outcome recorded |
| Phase 2 | NCT04570592 Comparator | Oct 2020 → Apr 2021 | — | Universiti Sains Malaysia | Unknown | No outcome recorded |
| Phase 2 | NCT04085393 Comparator | Aug 2020 | chemotherapy-induced toxicity | University of Alabama at Birmingham | Withdrawn | No outcome recorded |
| Phase 2 | NCT03483870 Comparator | Jun 2018 → Oct 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT02588547 Comparator | Nov 2015 → May 2017 | benign shuddering attacks | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT00186628 Background | Jun 2005 → Nov 2010 | mantle cell lymphoma, mast cell leukemia | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00450801 Background | Apr 2004 → Jul 2015 | lymphoma | University of Miami | Completed | No outcome recorded |
| Phase 2 | NCT00003817 Background | Oct 1999 → Jul 2001 | cancer of unknown primary site | Gary Morrow | Completed | No outcome recorded |
| Phase 2 | NCT00666783 Comparator | — | chemotherapy-induced toxicity | Xijing Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT05314257 Comparator | Apr → Nov 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT05711823 Comparator | Jul → Dec 2024 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04918862 Comparator | Jan → May 2021 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT04437017 Comparator | Feb 2020 → May 2022 | chemotherapy-induced toxicity | Fifth Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT04613726 Comparator | Dec 2018 → Dec 2019 | hypotensive disorder | Ataturk University | Completed | No outcome recorded |
| Phase 3 | NCT02116530 Background | Aug 2014 → Apr 2015 | cancer of unknown primary site, hematopoietic and lymphoid cell neoplasm | Alliance for Clinical Trials in Oncology | Completed | Met primary |
| Phase 3 | NCT01499849 Background | Feb 2012 → May 2014 | chemotherapy-induced toxicity | Tesaro, Inc. | Completed | Met primary |
| Phase 3 | NCT01500213 Background | Feb 2012 → Mar 2014 | chemotherapy-induced toxicity | Tesaro, Inc. | Completed | Met primary |
| Phase 3 | NCT01500226 Background | Feb 2012 → Feb 2014 | chemotherapy-induced toxicity | Tesaro, Inc. | Completed | Met primary |
| Phase 3 | NCT00952341 Background | Aug 2009 → Apr 2010 | chemotherapy-induced toxicity | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT00359567 Comparator | Jul 2006 → May 2007 | chemotherapy-induced toxicity | Taiho Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 3 | NCT00272285 Comparator | Jan 2006 → Dec 2007 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 4 | NCT06540885 Comparator | Jan 2025 → Jul 2026 overdue | idiopathic scoliosis | University of Malaya | Recruiting | No outcome recorded |
| Phase 4 | NCT06513806 Comparator | Aug → Sep 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05632224 Comparator | Nov 2022 → Jan 2023 | — | Baskent University | Unknown | No outcome recorded |
| Phase 4 | NCT04899817 Comparator | May 2021 → Mar 2022 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT04817189 Comparator | Feb 2021 → Jul 2024 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | Met primary |
| Phase 4 | NCT04150614 Comparator | May 2020 → Jul 2026 overdue | chemotherapy-induced toxicity | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 4 | NCT03091881 Comparator | Mar → Sep 2018 | — | Suez Canal University | Completed | No outcome recorded |
| Phase 4 | NCT03180229 Comparator | May → Sep 2017 | cholelithiasis | Diskapi Yildirim Beyazit Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03017391 Comparator | Jan 2017 → Apr 2018 | cancer | Radboud University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02441894 Background | Apr 2015 → Feb 2016 | prostate cancer | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT01636947 Background | Dec 2012 → Aug 2014 | — | Merck Sharp & Dohme LLC | Completed | Missed primary |
| Phase 4 | NCT01352130 Comparator | Mar → Apr 2007 | — | Tata Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00415103 Comparator | Nov 2006 → Sep 2009 | leukemia, lymphoma | PETHEMA Foundation | Completed | No outcome recorded |
| — | NCT06437236 Comparator | Apr → Dec 2024 | — | Sohag University | Unknown | No outcome recorded |
| — | NCT06762860 Comparator | Jan 2024 → Jan 2025 | benign shuddering attacks | Minia University | Unknown | No outcome recorded |
| — | NCT06778460 Background | May 2023 → Mar 2027 expected | chronic pain syndrome | West China Hospital | Recruiting | No outcome recorded |
| — | NCT05474001 Comparator | Jun 2022 → Aug 2023 | — | Mohamed Youssef Mohamed | Unknown | No outcome recorded |
| — | NCT06000137 Background | Feb 2022 → Jan 2023 | — | Eye & ENT Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT05230654 Background | Feb → Apr 2022 | chemotherapy-induced toxicity | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| — | NCT04873284 Background | May → Dec 2021 | chemotherapy-induced toxicity, childhood malignant neoplasm | Shanghai Children's Medical Center | Unknown | Met primary |
| — | NCT03434340 Background | Jun 2018 → Mar 2019 | — | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT03956446 Background | Sep 2014 → Dec 2027 expected | tick-borne encephalitis | University Medical Centre Ljubljana | Recruiting | No outcome recorded |
| — | NCT02463942 Background | Sep 2014 → Sep 2020 | tick-borne encephalitis | University Medical Centre Ljubljana | Unknown | No outcome recorded |
| — | NCT00293384 Background | Oct 2004 → Jun 2009 | breast cancer, gestational trophoblastic neoplasm, leukemia, myelodysplastic syndrome +5 | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 16
| Date | Issuer | Release |
|---|---|---|
| 2016-08-10 | Heron Therapeutics | Regulatory Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting herontx.com ↗
Heron Therapeutics, Inc. (NASDAQ:HRTX), today announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection. |
| 2015-09-28 | Heron Therapeutics | Results Heron Therapeutics Announces Oral Presentation of Data from Completed Phase 3 MAGIC Study for SUSTOL® at the ASCO Breast Cancer Symposium herontx.com ↗
These data were presented in an oral presentation and poster titled “Phase III Study of APF530 versus Ondansetron with a Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: MAGIC Trial.” |
| 2015-09-18 | Heron Therapeutics | Regulatory Heron Therapeutics Announces FDA Acceptance of New Drug Application for SUSTOL® herontx.com ↗
The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of January 17, 2016. |
| 2015-07-20 | Heron Therapeutics | Regulatory Heron Therapeutics Resubmits SUSTOL® New Drug Application to FDA herontx.com ↗ |
| 2012-10-16 | Heron Therapeutics | Regulatory A.P. Pharma Announces PDUFA Action Date for APF530 New Drug Application Resubmission herontx.com ↗
A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s resubmission of its New Drug Application (NDA) for APF530. |
| 2012-09-28 | Heron Therapeutics | Regulatory A.P. Pharma Resubmits New Drug Application for APF530, a Product Candidate for the Prevention of Chemotherapy-Induced Nausea and Vomiting herontx.com ↗
A.P. Pharma, Inc. (OTCBB: APPA), a specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead product candidate, APF530, for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). |
| 2011-04-25 | Heron Therapeutics | Regulatory A.P. Pharma Provides Regulatory Update on APF530 NDA herontx.com ↗
The FDA acknowledged that the single-syringe design would be an improvement, suggested certain labeling enhancements, and requested additional, non-clinical, human factors studies be conducted prior to resubmission. |
| 2010-03-19 | Heron Therapeutics | Regulatory A.P. Pharma Receives FDA Complete Response Letter for APF530 herontx.com ↗
A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration (FDA or Agency) regarding its New Drug Application (NDA) for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting (CINV). |
| 2009-07-20 | Heron Therapeutics | Regulatory A.P. Pharma Announces FDA Acceptance of APF530 New Drug Application for Chemotherapy-Induced Nausea and Vomiting herontx.com ↗
A.P. Pharma, Inc. (Nasdaq:APPA), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for APF530 for the potential treatment of chemotherapy-induced nausea and vomiting (CINV). |
| 2008-11-05 | Heron Therapeutics | Results A.P. Pharma Reports Results for the Third Quarter 2008 herontx.com ↗
The additional data from the Phase 3 study provided herein includes predetermined secondary efficacy endpoints and safety data that were not available at the time the top-line data were released. |
| 2008-09-30 | Heron Therapeutics | Results A.P. Pharma Announces Positive Phase 3 Results with APF530 in the Prevention of CINV herontx.com ↗
A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, announced today positive results from its pivotal Phase 3 study comparing the efficacy of APF530 (the Company's proprietary, sustained release formulation of granisetron) with Aloxi(R) for the prevention of chemotherapy induced nausea and vomiting (CINV). |
| 2008-01-03 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Generic Kytril® Injection And Tablets tevapharm.com ↗
the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Applications (ANDA) |
| 2005-09-29 | Heron Therapeutics | Results A.P. Pharma Reports All Clinical Endpoints Achieved in APF530 Phase 2 Trial; Conference Call to Begin at 11:00 A.M. Eastern Time Tuesday, October 4, 2005 herontx.com ↗
All clinical endpoints were achieved and results support advancement of APF530 into pivotal clinical trials. |
| 2005-08-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Granisetron Hydrochloride Injection tevapharm.com ↗
the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDAs for Granisetron HCl Injection, 1 mg/mL single dose vials and Granisetron HCl Injection, 4 mg/4mL in multi-dose vials. |
| 2004-11-15 | Heron Therapeutics | Results A.P. Pharma Reports Third Quarter Financial Results; APF530 Phase 1 Study Successfully Completed herontx.com ↗
APF530 successfully met its target kinetic profile in healthy volunteers. |
| 2004-08-12 | Heron Therapeutics | Results A.P. Pharma Reports Preliminary Clinical Data Results from Studies Using APF112 AND APF530; Conference Call to Begin Today at 12:00 Noon ET/9:00 a.m. PT herontx.com ↗
First dosing in six healthy human volunteers showed sustained blood levels over four days following administration. |
All press releases naming this drug 33 releases
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 107 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Granisetron | “5HT3 (5-Hydroxytryptamine 3) antagonists (ondansetron, granisetron or tropisetron) used as the local institutional standard of care will be permitted, although the preferential...” NCT01843868 ↗100“The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy.” PMID 25465680 ↗ Dec 2014 “APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV).” PMID 26997579 ↗ Mar 2016 “Patients will receive symptomatic therapy (paracetamol, Lekadol®, granisetron, Kytril®, metamizol, Analgin®, parenteral hydration with saline).” NCT02463942 ↗ “Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S\>0.6m2, 4 mg/dose, q12h , IV/PO.” NCT05230654 ↗ “SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV)” NCT05434663 ↗ “Another PCIA device contained sufentanil 2 ug/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.” NCT06778460 ↗ “as compared to Granisetron IV Injection and Granisetron Tablet in healthy Volunteers.” NCT02563951 ↗ “Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy” NCT00415103 ↗ “Sancuso Patch (Granisetron) in Chemotherapy-induced Nausea and Vomiting (CINV)” NCT01659775 ↗ “Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome” NCT04645953 ↗ |
| Known as | APF530 | “AIM: APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy-induced nausea and vomiting (CINV).” PMID 26997579 ↗ Mar 2016 |
| Known as | AZ-010 | “A single oral dose of 0.5 mg AZ-010 (Staccato Granisetron) administered to 8 subjects” NCT04200092 ↗1“Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome” NCT04645953 ↗ |
| Known as | Bema granisetron | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | BRL 43694 | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | BRL 43694A | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | G Setron | “the effect of the antiemetic drug Granisetron (G Setron 1 mg in 1 ml ampule) in reducing the incidence of hypotension” NCT03091881 ↗ |
| Known as | GERSC | “GERSC is a new, subcutaneously (SC) administered polymeric formulation of Granisetron that was developed to provide slow, controlled, and sustained release of granisetron to...” NCT04085393 ↗ |
| Known as | GNS | “Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers” NCT02563951 ↗ |
| Known as | Granisetron (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | GRANISETRON EXTENDED RELEASE INJECTION | “GRANISETRON EXTENDED RELEASE INJECTION (GERSC)” NCT04085393 ↗ |
| Known as | Granisetron hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | granisetron hydrochloride | “Kytril® (granisetron hydrochloride)” NCT00873197 ↗ |
| Known as | Granisetron Hydrochloride Nasal Spray | “Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers” NCT02563951 ↗ |
| Known as | Granisetron hydrochloride preservative free | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Granisetron TDS | “Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)” NCT00890565 ↗ |
| Known as | Granisetron Transdermal Delivery System | “The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in the prevention of CINV...” NCT01662687 ↗ |
| Known as | Granisetron Transdermal System | “The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy.” PMID 25465680 ↗ Dec 2014 |
| Known as | Granisol | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Granisteron hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Granitryl | “Granisetron (Granitryl 1 mg/ml, ampules, EGYPHARMA, Egypt)” NCT07401745 ↗ |
| Known as | GTDS | “The study is to demonstrate non-inferiority of the Granisetron Transdermal Delivery System (GTDS) compared with the intravenous and oral Granisetron in the prevention of CINV...” NCT01662687 ↗1“OBJECTIVE: To evaluate the safety and efficacy of the granisetron transdermal delivery system (GTDS) combined with Dexamethasone for preventing” PMID 39026165 ↗ Jul 2024 |
| Known as | GTS | “The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy.” PMID 25465680 ↗ Dec 2014 |
| Known as | intravenous graniseton | “Drug: intravenous graniseton” NCT05474001 ↗ |
| Known as | Kytril | “Patients should be administered Kytril (granisetron) 1 mg orally, under fasted conditions (-2 to 2 hours away from meals), 30 minutes prior to administration of the AZD1775...” NCT03333824 ↗1“The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations” NCT00502437 ↗ |
| Known as | LY-278584 | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Neoset | “Patients in Group G received 3 mg granisetron (Neoset, Deva, Istanbul)” NCT06454825 ↗ |
| Known as | NSC-759839 | ChEMBL registry synonym — accepted as the source's own label CHEMBL289469 ↗ |
| Known as | Sancuso | “Sancuso Patch (Granisetron) in Chemotherapy-induced Nausea and Vomiting (CINV)” NCT01659775 ↗4“Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)” NCT00890565 ↗ “Transdermal Granisetron (Sancuso® Patch)” NCT01596426 ↗ “Transdermal Granisetron (Sancuso® Patch)” NCT01596413 ↗ |
| Known as | SP-01 | “A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting” NCT01937156 ↗ |
| Known as | Staccato Granisetron | “A single oral dose of 0.5 mg AZ-010 (Staccato Granisetron) administered to 8 subjects” NCT04200092 ↗1“Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome” NCT04645953 ↗ |
| Known as | SUSTOL | “SUSTOL® (granisetron) extended-release injection, for subcutaneous use for prevention of chemotherapy induced nausea and vomiting (CINV)” NCT05434663 ↗ |
| Action | Inhibit | “Patients receive their scheduled chemotherapy regimen containing doxorubicin and their scheduled oral 5 hydroxytryptamine 3 receptor antagonist antiemetic (ondansetron,...” NCT00020657 ↗1“Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL289469 ↗ |
| Modality | Other / unclassified | “Granisetron transdermal delivery system (GTDS) is the first 5-HT3 drug” NCT04912271 ↗ |
| Route | Oral | “Arm III: Patients receive oral granisetron hydrochloride once daily for 14 days.” NCT00004219 ↗ |
| Target | HTR3A | “Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL289469 ↗ |